MedTrace Logo

Nicotine Replacement Therapy and Cardiovascular Disease

NCT02195739 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 61050

Last updated 2014-10-01

No results posted yet for this study

Summary

The aim of this study is to compare the cardiovascular disease event rate in smokers undertaking pharmacologically unaided smoking cessation attempts (the non-exposed group) with the event rate in smokers attempting smoking cessation assisted by pharmacological interventions - by nicotine replacement therapy (as any, or a combination, of: nasal spray, transdermal patches, inhaler or gum and tablets) or other pharmacological smoking cessation aids (e.g. bupropion \[Zyban®\] and varenicline \[Champix®\]) - in a representative UK primary care population.

Conditions

  • Smoking Cessation

Sponsors & Collaborators

  • Research in Real-Life Ltd

    lead NETWORK

Principal Investigators

  • David Price, Prof, MD · University of Aberdeen

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-03-31
Completion
2014-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195739 on ClinicalTrials.gov